Melanoma

Most recent

Canadian perspective by Dr. Teresa Petrella

September 2011 ASCO 2011 New Treatment Strategies and Ongoing Clinical Research for Metastatic Melanoma Metastatic melanoma is a devastating disease with a very poor prognosis and historically, therapeutic options have been limited. However, new agents and treatment...

Canadian Perspective on the Clinical Management of Metastatic Melanoma

NE Oncology Issue - September 2012 Teresa Petrella, MD, FRCPC;1 Scott Ernst, MD, FRCPC;2 Alan Spatz, MD;3 Joel Claveau, MD, FRCPC;4 Ralph Wong, BSc, MD, FRCPC;5 Michael Smylie, MD, FRCPC6 1Division of Medical Oncology/Hematology, Odette Cancer Centre, Toronto,...

Twitter feed

Video: Dr. Mark Vincent Discusses Outcomes in Pancreatic Adenocarcinoma Patients with Genetic Alterations in DNA Da… https://t.co/35E7MSeX3V
h J R
RT @medoncdoc: CO26. first evidence of survival benefit in MSS patients using immunotherapy. 6.6 mo vs 4.1 mo.#GI19 @CDNCancerTrials great…
h J R
RT @tehfem: Adjuvant HIPEC in CRC at high risk for peritoneal mets No benefit #GI19 https://t.co/tYIw9B3eme
h J R
RT @GillSharlene: How long to optimally wait for resection after neoadjuvant therapy for early stage rectal cancer? Looks like the answer…
h J R
Video: Dr. Winson Cheung on Prognostic Factors Associated with Long-Term Survival in Chemotherapy-Treated Advanced… https://t.co/yBP1srRQkb
h J R

Other

Canadian perspective by Dr. Teresa Petrella

NE Oncology Issue - September 2011 Metastatic melanoma is a devastating disease with a very poor prognosis and historically, therapeutic options have been limited. However, new agents and treatment strategies are changing the landscape of the management of melanoma....

Canadian Perspective by Dr. Laneuville

NE Oncology Issue - January 2007 There is no reliable data available on the incidence and prevalence of myelodysplastic syndromes (MDS) and chronic myeloproliferative disorders (CMD) in Canada. It has thus been difficult to estimate the resources that might be...

Canadian Perspective by Dr. Laneuville

NE Oncology Issue - January 2007 Myelodysplasia and AML are thought to, in part, result from epigenetic silencing of certain genes through promoter methylation. This preclinical study has shown that the optimal re-expression of genes silenced through this mechanism...

Twitter feed

Video: Dr. Mark Vincent Discusses Outcomes in Pancreatic Adenocarcinoma Patients with Genetic Alterations in DNA Da… https://t.co/35E7MSeX3V
h J R
RT @medoncdoc: CO26. first evidence of survival benefit in MSS patients using immunotherapy. 6.6 mo vs 4.1 mo.#GI19 @CDNCancerTrials great…
h J R
RT @tehfem: Adjuvant HIPEC in CRC at high risk for peritoneal mets No benefit #GI19 https://t.co/tYIw9B3eme
h J R
RT @GillSharlene: How long to optimally wait for resection after neoadjuvant therapy for early stage rectal cancer? Looks like the answer…
h J R
Video: Dr. Winson Cheung on Prognostic Factors Associated with Long-Term Survival in Chemotherapy-Treated Advanced… https://t.co/yBP1srRQkb
h J R